AU2002328792A1 - Method for preparation of lna phosphoramidites - Google Patents

Method for preparation of lna phosphoramidites

Info

Publication number
AU2002328792A1
AU2002328792A1 AU2002328792A AU2002328792A AU2002328792A1 AU 2002328792 A1 AU2002328792 A1 AU 2002328792A1 AU 2002328792 A AU2002328792 A AU 2002328792A AU 2002328792 A AU2002328792 A AU 2002328792A AU 2002328792 A1 AU2002328792 A1 AU 2002328792A1
Authority
AU
Australia
Prior art keywords
preparation
lna phosphoramidites
cyanoethyl
phosphoramidites
lna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002328792A
Other languages
English (en)
Inventor
Troels Koch
Daniel Sejer Pedersen
Christoph Rosenbohm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Innovation Center Copenhagen AS
Original Assignee
Santaris Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santaris Pharma AS filed Critical Santaris Pharma AS
Publication of AU2002328792A1 publication Critical patent/AU2002328792A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/02—Phosphorylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Luminescent Compositions (AREA)
  • Saccharide Compounds (AREA)
AU2002328792A 2001-07-12 2002-07-12 Method for preparation of lna phosphoramidites Abandoned AU2002328792A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200101095 2001-07-12
DKPA200101095 2001-07-12
PCT/DK2002/000488 WO2003006475A2 (en) 2001-07-12 2002-07-12 Method for preparation of lna phosphoramidites

Publications (1)

Publication Number Publication Date
AU2002328792A1 true AU2002328792A1 (en) 2003-01-29

Family

ID=8160624

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002328792A Abandoned AU2002328792A1 (en) 2001-07-12 2002-07-12 Method for preparation of lna phosphoramidites

Country Status (7)

Country Link
EP (1) EP1409497B1 (https=)
JP (1) JP4402454B2 (https=)
AT (1) ATE287413T1 (https=)
AU (1) AU2002328792A1 (https=)
DE (1) DE60202681T2 (https=)
DK (1) DK1409497T3 (https=)
WO (1) WO2003006475A2 (https=)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003085110A2 (en) 2002-04-05 2003-10-16 Santaris Pharma A/S Oligomeric compounds for the modulation hif-1alpha expression
US7713738B2 (en) 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
PT1592793E (pt) 2003-02-10 2009-09-30 Santaris Pharma As Compostos oligoméricos para a modulação da expressão de survivina
CA2519860C (en) 2003-03-21 2018-01-16 Santaris Pharma A/S Short interfering rna (sirna) analogues
RU2377301C2 (ru) 2003-12-23 2009-12-27 Сантарис Фарма А/С ОЛИГОМЕРНОЕ СОЕДИНЕНИЕ, ПОНИЖАЮЩЕЕ ЭКСПРЕССИЮ ЧЕЛОВЕЧЕСКОГО ГЕНА Bcl-2, КОНЪЮГАТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ ОЛИГОМЕРНОГО СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ РАКА
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
KR20070095882A (ko) 2004-11-09 2007-10-01 산타리스 팔마 에이/에스 Ｌｎａ 올리고뉴클레오티드 및 암의 치료
AU2005304112B2 (en) 2004-11-09 2009-06-04 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
EP1971371B1 (en) 2005-12-01 2015-08-05 Pronai Therapeutics, Inc. Cancer therapies and pharmaceutical compositions used therein
WO2007107162A2 (en) 2006-03-23 2007-09-27 Santaris Pharma A/S Small internally segmented interfering rna
EP2666859B1 (en) 2006-04-03 2019-01-02 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
CA2648132C (en) 2006-04-03 2019-05-28 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
CA2681406A1 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S Rna antagonist compounds for the inhibition of apo-b100 expression
WO2008113832A2 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA
ES2798758T3 (es) 2007-06-06 2020-12-14 Sarepta Therapeutics Inc Proteínas variantes de empalme her2 y her3 solubles, oligonucleótidos de cambio de empalme y su uso en el tratamiento de enfermedades
WO2009027978A1 (en) 2007-08-30 2009-03-05 Hadasit Medical Research Services & Development Ltd. NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS
EP2623599B1 (en) 2007-10-04 2019-01-02 Roche Innovation Center Copenhagen A/S Micromirs
EP2212437A4 (en) 2007-11-07 2011-09-28 Univ British Columbia MICROFLUIDIC DEVICE AND METHOD OF USING THE DEVICE
EP2268811A1 (en) 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
ES2541442T3 (es) 2008-08-01 2015-07-20 Roche Innovation Center Copenhagen A/S Modulación mediada por microARN de factores estimulantes de colonias
ES2599979T3 (es) 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
WO2011105900A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011105901A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 9 (c9) and uses thereof
WO2011105902A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-beta (c8-beta) and uses thereof
GB201012418D0 (en) 2010-07-23 2010-09-08 Santaris Pharma As Process
WO2012027206A1 (en) 2010-08-24 2012-03-01 Merck Sharp & Dohme Corp. SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
BR112015010220A2 (pt) 2012-11-05 2017-12-05 Pronai Therapeutics Inc métodos de utilização de biomarcadores para tratamento de câncer
WO2014108759A1 (en) 2013-01-14 2014-07-17 Pierfrancesco Tassone INHIBITORS OF miRNAs 221 AND 222 FOR ANTI-TUMOR ACTIVITY IN MULTIPLE MYELOMA
ES2770667T3 (es) 2013-06-27 2020-07-02 Roche Innovation Ct Copenhagen As Oligómeros antisentido y conjugados que se dirigen a PCSK9
WO2015075166A1 (en) 2013-11-22 2015-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of a bacterial infection
US9765332B2 (en) 2014-01-29 2017-09-19 Inserm (Institut National De La Sante Et De La Recherche Medicale) Oligonucleotides and methods for inhibiting or reducing bacterial biofilms
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
WO2016041058A1 (en) 2014-09-18 2016-03-24 The University Of British Columbia Allele-specific therapy for huntington disease haplotypes
CN107109411B (zh) 2014-10-03 2022-07-01 冷泉港实验室 核基因输出的定向增加
JP6835826B2 (ja) * 2015-08-24 2021-02-24 ロシュ イノベーション センター コペンハーゲン エーエス Ｌｎａ−ｇプロセス
EP3359685B1 (en) 2015-10-09 2026-01-28 University Of Southampton Modulation of gene expression for deregulated protein expression
EP3933041B1 (en) 2015-12-14 2024-01-31 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant retardation
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
WO2018024849A1 (en) 2016-08-03 2018-02-08 Aalborg Universitet ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
SG11202001590RA (en) 2017-08-25 2020-03-30 Stoke Therapeutics Inc Antisense oligomers for treatment of conditions and diseases
WO2019076919A1 (en) 2017-10-17 2019-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) COMBINED TREATMENT OF CYSTIC FIBROSIS
US12060558B2 (en) 2018-05-04 2024-08-13 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
KR20210134003A (ko) 2019-02-27 2021-11-08 스톡 테라퓨틱스, 인크. 병태 및 질환의 치료를 위한 안티센스 올리고머
US20220251567A1 (en) 2019-07-10 2022-08-11 Inserm (Institut National De La Santè Et De La Recherche Médicale) Methods for the treatment of epilepsy
IT201900017234A1 (it) 2019-09-25 2021-03-25 Int Centre For Genetic Engineering And Biotechnology Anti-miRNA per il trattamento del leiomioma
WO2021074657A1 (en) 2019-10-17 2021-04-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination treatment for cystic fibrosis
IL292286A (en) * 2019-10-18 2022-06-01 Daiichi Sankyo Co Ltd Production method for bicyclic phosphoramidite
CA3161586A1 (en) * 2019-11-13 2021-05-20 Nippon Shinyaku Co., Ltd. Method for producing oligonucleic acid compound
US20230016983A1 (en) 2019-11-19 2023-01-19 lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Antisense oligonucleotides and thier use for the treatment of cancer
BR112022022889A2 (pt) 2020-05-11 2023-04-04 Stoke Therapeutics Inc Oligômeros antissentido de opa1 para tratamento de condições e doenças
KR20230050336A (ko) 2020-07-10 2023-04-14 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) 뇌전증을 치료하기 위한 방법과 조성물
WO2022124410A1 (ja) * 2020-12-11 2022-06-16 ヤマサ醤油株式会社 シトシン型架橋型ヌクレオシドアミダイト結晶及びその製造方法
IL304956A (en) 2021-02-12 2023-10-01 Merand Pharmaceuticals Inc Agents, compositions, and methods for the treatment of hypoxia and ischemia-related disorders
US20240182889A1 (en) 2021-03-26 2024-06-06 Neumirna Therapeutics Aps Microrna-27b inhibitors
EP4313073A1 (en) 2021-03-26 2024-02-07 Neumirna Therapeutics ApS Microrna-134 inhibitors
JP2024522272A (ja) 2021-06-04 2024-06-13 ニューミルナ セラピューティクス エーピーエス アデノシンキナーゼを標的とするアンチセンスオリゴヌクレオチド
EP4389892A4 (en) 2021-08-17 2025-12-10 Korea Advanced Inst Sci & Tech Antisense oligonucleotide targeting the CAV3.1 gene and its uses
CA3228833A1 (en) 2021-08-19 2023-02-23 Neumirna Therapeutics Aps Antisense oligonucleotides targeting adenosine kinase
JP7772362B2 (ja) * 2021-12-21 2025-11-18 シンクレスト株式会社 人工核酸モノマーの製造方法
WO2023152369A1 (en) 2022-02-14 2023-08-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis
EP4558149A1 (en) 2022-07-21 2025-05-28 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating chronic pain disorders
EP4332239A1 (en) 2022-08-30 2024-03-06 Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. Mir-based assay for gastro-entero-pancreatic neuroendocrine tumor diagnosis and prognosis
EP4646478A1 (en) 2023-01-06 2025-11-12 Institut National de la Santé et de la Recherche Médicale Intravenous administration of antisense oligonucleotides for the treatment of pain
EP4450626A1 (en) 2023-04-21 2024-10-23 IFOM - Istituto Fondazione di Oncologia Molecolare ETS Fnip2 inhibitors for treating ataxia telangiectasia
WO2025008406A1 (en) 2023-07-04 2025-01-09 Institut National de la Santé et de la Recherche Médicale Antisense oligonucleotides and their use for the treatment of cancer
EP4512899A1 (en) 2023-08-23 2025-02-26 Lipigon Pharmaceuticals AB Angptl4 aso compositions for treatment of atherosclerosis in humans
CN117233282B (zh) * 2023-09-14 2024-12-20 上海奥锐特生物科技有限公司 2-氰乙基-n,n,n’,n’-四异丙基亚磷酰二胺的检测方法
WO2025237990A1 (en) 2024-05-14 2025-11-20 Institut National de la Santé et de la Recherche Médicale Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
WO2026061986A1 (en) 2024-09-17 2026-03-26 Institut National de la Santé et de la Recherche Médicale Antisense oligonucleotide (aso)-mediated down-regulation of cd33 to safely enrich for genetically modified cells
WO2026068729A1 (en) 2024-09-26 2026-04-02 Neumirna Therapeutics Aps Antimir-27b for treatment of parkinson's disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4800197A (en) * 1996-10-15 1998-05-11 Nexstar Pharmaceuticals, Inc. Improved coupling activators for oligonucleotide synthesis

Also Published As

Publication number Publication date
EP1409497A2 (en) 2004-04-21
EP1409497B1 (en) 2005-01-19
JP4402454B2 (ja) 2010-01-20
DE60202681D1 (de) 2005-02-24
WO2003006475A3 (en) 2004-02-26
WO2003006475A2 (en) 2003-01-23
ATE287413T1 (de) 2005-02-15
DK1409497T3 (da) 2005-05-30
JP2004536125A (ja) 2004-12-02
DE60202681T2 (de) 2006-01-12

Similar Documents

Publication Publication Date Title
AU2002328792A1 (en) Method for preparation of lna phosphoramidites
MY117948A (en) Nitride oxide synthase inhibitors.
AU2002224893A1 (en) Method for producing a part and device for carrying out this method
NZ503308A (en) Alpha-ketoamide multicatalytic protease inhibitors
GB9916405D0 (en) Compounds for mass spectrometry
ATE266030T1 (de) 1,4,7,10-tetraazabicyclo(8.2.2)tetradecan-2-on, verfahren zu ihrer herstellung und ihrer verwendung für die herstellung von tetraazamacrocyclen
AUPR549901A0 (en) Topical formulation containing tocopheryl phosphates
UA66792C2 (uk) Спосіб отримання 2-арил-3-арил-5-галогенпіридинів, що використовуються як інгібітори сох-2 (варіанти)
MX9801190A (es) Inhibidores de prolil endopeptidasa.
AU4559699A (en) Method of preparing phosphoramidites
AU8631698A (en) A process for the preparation of tetraazamacrocycles
AU2003240634A1 (en) Method for producing bicalutamide
BR9807785A (pt) Processo para a preparação do composto, e, composto
ZA200005110B (en) Process for preparing intermediates.
AU2002212241A1 (en) Method for producing chiral compounds
CA2328832A1 (en) Processes for preparing pesticidal intermediates
PT1250335E (pt) Processo e intermediarios para a preparacao de imidazopiridinas
AU6726998A (en) Method for producing 5-aminomethyl-2-chloropyridines
MY133098A (en) New nitromethyl ketones, process for preparing them and compositions containing them
IL154165A0 (en) Method for the production of imidazo-(1,2-c) (2,3)-benzodiazepines and intermediates in the production thereof
AU2003229729A1 (en) A process for the preparation of benazepril hydrochloride
AU8022398A (en) Novel method for preparing 2-trifluoro-methoxy-aniline
UA70975C2 (uk) Похідні 1,4-діарил-2-фтор-1-бутен-3-олу, спосіб їх одержання та способи одержання похідних 1,4-діарил-2-фтор-1,3-бутадієну і 1,4-діарил-2-фтор-2-бутену
WO2002020490A3 (en) Process to produce halo-4-phenoxyquinolines
PL347584A1 (en) Fluorinated 3,4-dihydroquinoline derivatives used as nos inhibitors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase